Curated News
By: NewsRamp Editorial Staff
October 23, 2026
QT Imaging Gets Buy Rating, $9 Target from D. Boral Capital
TLDR
- D. Boral Capital initiated QT Imaging with a Buy rating and $9 price target, citing revenue growth to $90.5 million by 2030.
- The $9 target uses a discounted cash flow analysis with a 15% discount rate and 1% terminal growth rate.
- QT Imaging's Breast Acoustic CT Scanner provides radiation-free, compression-free 3D breast imaging, improving comfort and safety for women.
- QT Imaging's scanner uses low-frequency sound waves to create 3D breast images without radiation or compression, especially aiding dense breast tissue.
Impact - Why it Matters
The Buy rating and optimistic revenue projections from D. Boral Capital underscore the market potential of QT Imaging’s radiation-free breast imaging technology. For patients, particularly those with dense breast tissue, this could mean access to a more comfortable and potentially more accurate alternative to traditional mammograms. For investors, the report highlights a compelling growth story in the medtech space, though risks around commercialization and reimbursement remain. As breast cancer screening continues to evolve, innovations like the Breast Acoustic CT™ Scanner could play a significant role in improving early detection and patient outcomes.
Summary
QT Imaging (NASDAQ: QTI), a medical technology company focused on advanced breast imaging, has received a Buy rating and a $9 price target from D. Boral Capital in an October 23, 2026 research report titled “Beyond the Mammogram.” Analyst Patrick McCann highlighted the growing adoption of the company’s Breast Acoustic CT™ Scanner, expanding international distribution, and potential applications beyond supplemental breast imaging. The scanner generates three-dimensional images without radiation, breast compression, or contrast injections, offering particular advantages for women with dense breast tissue. The report also noted potential uses in diagnostic evaluation and oncology treatment monitoring, pending further clinical validation.
D. Boral Capital projects revenue to rise from approximately $39 million in 2026 to $46.7 million in 2027 and $90.5 million by 2030, driven by increased scanner shipments, international regulatory approvals, and a developing direct-sales strategy targeting hospitals and imaging providers. The firm also forecasts adjusted EBITDA reaching $21.8 million by 2030, with recurring maintenance and software revenue contributing to growth. The $9 price target is derived from a discounted cash flow analysis using a 15% discount rate and a 1% terminal growth rate. The report acknowledged commercialization, manufacturing, financing, regulatory, and reimbursement risks that could affect the company’s growth trajectory. For the full report, visit https://ibn.fm/CpwHO.
QT Imaging Holdings, Inc. (Nasdaq: QTI) is dedicated to improving global health outcomes through innovative imaging systems that use low-frequency sound waves. The company’s strategy is rooted in the belief that medical imaging should be safe, affordable, accessible, and patient-centered. The report was distributed via InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, QT Imaging Gets Buy Rating, $9 Target from D. Boral Capital
